Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors

Zijiang Zhang; Yanchun Li; Haofei Hong; Zhimeng Wu

doi:10.1039/d5cc03243a

January 1, 2025Chemical Communications

Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors

View at Publisher

Ask AI

Bookmark

Share

Key Points

The approach effectively redirects vaccine-induced antibodies toward tumor cells.
Key findings reveal that engineered molecules improve targeting and potentially reduce side effects.
Analysis involves synthesizing and evaluating the performance of bifunctional antibody conjugates.
Implications could broaden immunotherapy applications, enhancing effectiveness in cancer treatment.

Implication

This study demonstrates a novel immunotherapy strategy using anti-HBV antibodies to target EGFR-positive tumors, suggesting new treatment avenues.

Abstract

This study introduces a novel immunotherapy strategy using engineered bifunctional molecules to redirect vaccine-induced anti-Hepatitis B Virus (HBV) antibodies toward Epidermal Growth Factor Receptor (EGFR)-positive tumors. The conjugates were synthesized...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68c1d24654b1d3bfb60f8455 https://doi.org/10.1039/d5cc03243a

View at Publisher

Ask AI

Bookmark

Share

Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Chemical Communications

Keep reading

More related papers

More from Chemical Communications